Martin McMahon
Affiliations: | Biochemistry and Molecular Biology | University of California, San Francisco, San Francisco, CA |
Area:
Molecular Biology, Cell Biology, Biochemistry, OncologyGoogle:
"Martin McMahon"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Ghazi PC, O'Toole KT, Srinivas Boggaram S, et al. (2024) Inhibition of ULK1/2 and KRAS controls tumor growth in preclinical models of lung cancer. Biorxiv : the Preprint Server For Biology |
| Parkman GL, Turapov T, Kircher DA, et al. (2023) Genetic silencing of AKT induces melanoma cell death via mTOR suppression. Molecular Cancer Therapeutics |
| Yu Y, Dai M, Huang L, et al. (2023) PTEN phosphatase inhibits metastasis by negatively regulating the Entpd5/IGF1R pathway through ATF6. Iscience. 26: 106070 |
| Vaishnavi A, Juan J, Jacob M, et al. (2022) Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis. Cancer Research |
| Parkman GL, Foth M, Kircher DA, et al. (2021) The role of PI3'-lipid signalling in melanoma initiation, progression and maintenance. Experimental Dermatology. 31: 43-56 |
| Foth M, McMahon M. (2021) Autophagy Inhibition in BRAF-Driven Cancers. Cancers. 13 |
| Truong A, Yoo JH, Scherzer M, et al. (2020) Chloroquine sensitizes GNAQ/11-mutated melanoma to MEK1/2 inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Vaishnavi A, Scherzer MT, Kinsey CG, et al. (2020) Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer. Cell Reports. 32: 107994 |
| Foth M, Parkman G, Battistone B, et al. (2020) RAC1 mutation is not a predictive biomarker for PI3'-kinase- selective pathway-targeted therapy. Pigment Cell & Melanoma Research |
| Vaishnavi A, Scherzer MT, Kinsey C, et al. (2020) Abstract 3769: Combined TRKA and MEK1/2 Inhibition Forestalls the Onset of Acquired Resistance in a New Preclinical Model of NTRK1+ Pancreatic Cancer Immunology. 80: 3769-3769 |